Advertisement

Topics

Roche’s Perjeta-based regimen cuts down breast cancer recurrence in phase 3 trial

05:55 EDT 6 Jun 2017 | Pharmaceutical Business Review

Roche’s Perjeta-based regimen has succeeded in a phase 3 trial by reducing the risk of recurrence of breast cancer by 19% in people with HER2-positive early breast cancer (eBC).

Original Article: Roche’s Perjeta-based regimen cuts down breast cancer recurrence in phase 3 trial

NEXT ARTICLE

More From BioPortfolio on "Roche’s Perjeta-based regimen cuts down breast cancer recurrence in phase 3 trial"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...